000141399 001__ 141399
000141399 005__ 20240229105126.0
000141399 0247_ $$2doi$$a10.1007/s00401-018-1844-9
000141399 0247_ $$2pmid$$apmid:29627952
000141399 0247_ $$2ISSN$$a0001-6322
000141399 0247_ $$2ISSN$$a1432-0533
000141399 0247_ $$2altmetric$$aaltmetric:35886209
000141399 037__ $$aDKFZ-2018-01905
000141399 041__ $$aeng
000141399 082__ $$a610
000141399 1001_ $$aKatz, Leah M$$b0
000141399 245__ $$aLoss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
000141399 260__ $$aHeidelberg$$bSpringer$$c2018
000141399 3367_ $$2DRIVER$$aarticle
000141399 3367_ $$2DataCite$$aOutput Types/Journal article
000141399 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1680782764_21949
000141399 3367_ $$2BibTeX$$aARTICLE
000141399 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141399 3367_ $$00$$2EndNote$$aJournal Article
000141399 520__ $$aEpigenetic patterns on the level of DNA methylation have already been shown to separate clinically relevant subgroups of meningiomas. We here set out to identify potential prognostic implications of epigenetic modification on the level of histones with focus on H3K27 trimethylation (H3K27me3). H3K27me3 was assessed by immunohistochemistry on 232 meningiomas from 232 patients. In 194 cases, trimethylation was detected in tumor cells. In 25 cases, staining was limited to vessels while all tumor cells were negative. Finally, 13 cases yielded equivocal staining patterns. Reduced abundance of H3K27me3 in cases with staining limited to vessels was confirmed by mass spectrometry on a subset of cases. Lack of staining for H3K27me3 in all tumor cells was significantly associated with more rapid progression (p = 0.009). In line, H3K27me3-negative cases were associated with a DNA methylation pattern of the more aggressive types among the recently introduced DNA methylation groups. Also, NF2 and SUFU mutations were enriched among cases with complete lack of H3K27me3 staining in tumor cells (p < 0.0001 and p = 0.029, respectively). H3K27me3 staining pattern added significant prognostic insight into WHO grade II cases and in the compound subset of WHO grade I and II cases (p = 0.04 and p = 0.007, respectively). However, it did not further stratify within WHO grade III cases. Collectively, these data indicate that epigenetic modifications beyond DNA methylation are involved in the aggressiveness of meningioma. It also suggests that H3K27me3 immunohistochemistry might be a useful adjunct in meningioma diagnostics, particularly for cases with WHO grade II histology or at the borderline between WHO grade I and II.
000141399 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000141399 588__ $$aDataset connected to CrossRef, PubMed,
000141399 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$eFirst author
000141399 7001_ $$aLiechty, Benjamin$$b2
000141399 7001_ $$aSilverman, Joshua$$b3
000141399 7001_ $$aZagzag, David$$b4
000141399 7001_ $$aSen, Rajeev$$b5
000141399 7001_ $$aWu, Peter$$b6
000141399 7001_ $$aGolfinos, John G$$b7
000141399 7001_ $$0P:(DE-HGF)0$$aReuss, David$$b8
000141399 7001_ $$aNeidert, Marian Christoph$$b9
000141399 7001_ $$aWirsching, Hans-Georg$$b10
000141399 7001_ $$aBaumgarten, Peter$$b11
000141399 7001_ $$aHerold-Mende, Christel$$b12
000141399 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b13
000141399 7001_ $$0P:(DE-He78)b15b56a6ed37417d476470c60c0140ff$$aHarter, Patrick$$b14
000141399 7001_ $$aWeller, Michael$$b15
000141399 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b16
000141399 7001_ $$aSnuderl, Matija$$b17
000141399 7001_ $$aSen, Chandra$$b18
000141399 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b19$$eLast author
000141399 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-018-1844-9$$gVol. 135, no. 6, p. 955 - 963$$n6$$p955 - 963$$tActa neuropathologica$$v135$$x1432-0533$$y2018
000141399 909CO $$ooai:inrepo02.dkfz.de:141399$$pVDB
000141399 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141399 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000141399 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000141399 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b15b56a6ed37417d476470c60c0140ff$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000141399 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000141399 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000141399 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000141399 9141_ $$y2018
000141399 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141399 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2017
000141399 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141399 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141399 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141399 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141399 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141399 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141399 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141399 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141399 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141399 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141399 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141399 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bACTA NEUROPATHOL : 2017
000141399 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000141399 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x1
000141399 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x2
000141399 9201_ $$0I:(DE-He78)L501-20160331$$kL501$$lDKTK Frankfurt$$x3
000141399 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x4
000141399 980__ $$ajournal
000141399 980__ $$aVDB
000141399 980__ $$aI:(DE-He78)C060-20160331
000141399 980__ $$aI:(DE-He78)G380-20160331
000141399 980__ $$aI:(DE-He78)G370-20160331
000141399 980__ $$aI:(DE-He78)L501-20160331
000141399 980__ $$aI:(DE-He78)L101-20160331
000141399 980__ $$aUNRESTRICTED